We are live on ! Find out more
CASI icon

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

53 hedge funds and large institutions have $63.2M invested in CASI Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,847% more capital inflows, than outflows

Capital inflows: $31.6M | Capital outflows: $638K

43% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 14

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

9.83% more ownership

Funds ownership: 11.38% → 21.21% (+9.8%)

4% more funds holding

Funds holding: 51 → 53 (+2)

Holders
53
Holders Change
+2
Holders Change %
+3.92%
% of All Funds
1.04%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
8
Increased
20
Reduced
14
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WSC
Wellington Shields & Co
New York
+$4.14M
2
Citadel Advisors
Citadel Advisors
Florida
+$268K
3
State Street
State Street
Massachusetts
+$247K
4
Morgan Stanley
Morgan Stanley
New York
+$175K
5
BlackRock
BlackRock
New York
+$163K

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$132K
2
Wells Fargo
Wells Fargo
California
-$117K
3
Marshall Wace
Marshall Wace
United Kingdom
-$104K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$75K
5
Credit Suisse
Credit Suisse
Switzerland
-$39K

CASI Hedge Fund Activity: Q4 2019 in Review

53 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2019, worth a combined $63.2M — up 74% from $36.4M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CASI positions and 6 closed out — a net gain of 2 holders — while 20 added to existing stakes and 14 trimmed.

The largest buyer was Wellington Shields & Co, opening a new position worth an estimated $4.14M. The largest seller was Northern Trust, cutting an estimated $132K.

  • 53 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2019, up from 51 in Q3 2019.
  • Funds reported $63.2M of CASI Pharmaceuticals stock for Q4 2019, up 74% quarter-over-quarter.
  • 8 funds opened new CASI Pharmaceuticals positions in Q4 2019 and 6 closed out, a net change of +2 holders.
  • The largest CASI Pharmaceuticals buyer in Q4 2019 was Wellington Shields & Co, an estimated $4.14M added.
  • The largest CASI Pharmaceuticals seller in Q4 2019 was Northern Trust, an estimated $132K sold.

Based on aggregated 13F filings for Q4 2019.